Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jan 27, 2024; 16(1): 33-40
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.33
Metabolic disease and the liver: A review
Márcia Vargas, Sheila de Castro Cardoso Toniasso, Patricia G Riedel, Camila Pereira Baldin, Francielle Lopes dos Reis, Robson Martins Pereira, Maria Carlota Borba Brum, Dvora Joveleviths, Mario Reis Alvares-da-Silva
Márcia Vargas, Dvora Joveleviths, Program of Graduate Science in Gastroenterology and Hepatology, Federal University of Rio Grande do Sul, Porto Alegre 90040-060, Rio Grande do Sul, Brazil
Sheila de Castro Cardoso Toniasso, Patricia G Riedel, Francielle Lopes dos Reis, Maria Carlota Borba Brum, School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre 90040-060, Brazil
Camila Pereira Baldin, Program of Graduate Science in Gastroenterology and Hepatology, Clinicas Hospital of Porto Alegre, Porto Alegre 90410000, Brazil
Robson Martins Pereira, Medicine Faculty Federal University of Rio Grande do Sul, Federal University of Rio Grande do Sul, Porto Alegre 90040-060, Brazil
Mario Reis Alvares-da-Silva, Division of Gastroenterology and Hepatology, Clinicas Hospital of Porto Alegre, Porto Alegre 90035007, Brazil
Author contributions: Vargas V, Joveleviths D, and Brum MCB contributed to design conceptualization, methodology, and investigation; Toniasso PGR, Reis FL, Pereira RL, and Baldin CP performed data curation and writing the original draft; Joveleviths D and Vargas M contributed to formal analysis, project administration, validation, and reviewing and editing; Joveleviths D and Vargas V wrote the final version; All authors read and approved the final draft for publication.
Conflict-of-interest statement: All the authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dvora Joveleviths, Doctor, PhD, Professor, Researcher, Program of Graduate Science in Gastroenterology and Hepatology, Federal University of Rio Grande do Sul, 90040-060, Porto Alegre 90035-002, Rio Grande do Sul, Brazil. dvorajov@gmail.com
Received: October 10, 2023
Peer-review started: October 10, 2023
First decision: October 16, 2023
Revised: November 6, 2023
Accepted: January 5, 2024
Article in press: January 5, 2024
Published online: January 27, 2024
Processing time: 104 Days and 17.2 Hours
Core Tip

Core Tip: Metabolic dysfunction-associated steatotic liver disease must be prevented in primary care by focusing on risk factors for metabolic syndrome and noninvasive fibrosis scores so that early detection is possible. To avoid a late diagnosis, primary care physicians need to reinforce in their routine examinations the need for lifestyle changes through healthy diet and exercise and implement pharmacological treatment when disease progression with the presence of fibrosis is identified. The treatment must be individualized, and in many cases several pharmacological options may be used to avoid disease progression, resulting in multisystemic involvement.